Posaconazole therapeutic drug monitoring: a reference laboratory experience.
about
Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infectionsPharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia.Intracellular concentrations of posaconazole in different compartments of peripheral blood.Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based methodInvasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational sUltra-performance liquid chromatography mass spectrometry and sensitive bioassay methods for quantification of posaconazole plasma concentrations after oral dosing.Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis.Failure of posaconazole therapy in a renal transplant patient with invasive aspergillosis due to Aspergillus fumigatus with attenuated susceptibility to posaconazolePosaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer.Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience.Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring.Therapeutic drug monitoring of posaconazole in allogeneic hematopoietic stem cell transplantation patients who develop gastrointestinal graft-versus-host disease.Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration.Therapeutic drug monitoring of posaconazole in patients with acute myeloid leukemia or myelodysplastic syndrome.Prospective phase II single-center study of the safety of a single very high dose of liposomal amphotericin B for antifungal prophylaxis in patients with acute myeloid leukemia.Antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia: dose intensification coupled with avoidance of proton pump inhibitors is beneficial in shortening time to effective concentrations.Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults.Use of posaconazole in the treatment of invasive fungal infections.Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections.Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics.Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method.Reflections on the approach to treatment of a mycologic disaster.Fatal breakthrough infection with Fusarium andiyazi: new multi-resistant aetiological agent cross-reacting with Aspergillus galactomannan enzyme immunoassay.Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome.A reference laboratory experience of clinically achievable voriconazole, posaconazole, and itraconazole concentrations within the bloodstream and cerebral spinal fluidComparing Azole Plasma Trough Levels in Lung Transplant Recipients: Percentage of Therapeutic Levels and Intrapatient VariabilityPrevention of Invasive Aspergillus Fungal Infections with the Suspension and Delayed-Release Tablet Formulations of Posaconazole in Patients with Haematologic Malignancies.Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America.
P2860
Q26771180-AD940D13-0DB5-4CC2-B54B-C67F345D2BB7Q33764269-D6C34006-C01F-4021-AB59-2E3E1695A332Q33962775-A6A23A03-EB56-4DA7-8DA7-0BF0BC624EC2Q34108484-0D4FAFB4-5616-44DC-AE13-0FA2895958C2Q34288593-7BC2CA8D-D440-4DEC-B6D9-015EB0C08CA7Q34309527-8FA98B24-1950-464F-9137-715AF03C0088Q34596750-229A0E11-0403-4E45-83CD-E266E54E13E4Q35065903-64E808E4-E666-4301-86F7-6900B5A32473Q35262607-6F82CF85-ECA7-4B66-912D-9EF0C87FB7B1Q35944724-65C0596E-00F3-46D3-8248-84728D5ACCCBQ36018743-573A76F0-E628-4325-815F-F706FF448822Q36276966-616043CC-8834-4508-B43D-92D496B3531EQ36364013-1E456C5B-F7EE-4BD4-BA5C-1460AEF2BC63Q36396203-53B0E70B-980A-48A9-BD39-8C7A7628ACB4Q37026715-5D400419-222D-41E4-A37C-31A199CEF038Q37335720-2D49104F-CB7C-4226-9E77-E7FF8A671AA0Q37450660-E8134E6A-024D-4356-9C01-4BD73F5F0950Q37810083-173AD1DA-4B05-4A1C-A7C1-F747A5158A2BQ37813420-D3F70566-F5E7-4A4D-A8EA-2D04E74D1514Q37904672-805BB585-D5AB-4931-9615-D23181956587Q39364669-C2A35F8D-B5D4-4FDD-8F97-050A1E98D509Q39767419-6BA12492-F7F0-4EC0-BA75-5B58B5921BCCQ40215030-4CD75A8D-B70A-406B-B85B-68057B679BBDQ40298087-B72124D1-23DD-4AB7-9CD0-75DAD714F4E6Q41907424-1F1A168A-CB02-4371-8E96-A5A7B178A087Q41991703-872E0354-15FD-4F72-A20F-00D7FFE22ABEQ48157814-1DBD332C-018F-4656-BF92-0FC38CF1291BQ51617424-FF4D3E92-EE3D-4CEC-9B0B-D36DEF19FEF0
P2860
Posaconazole therapeutic drug monitoring: a reference laboratory experience.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Posaconazole therapeutic drug monitoring: a reference laboratory experience.
@en
Posaconazole therapeutic drug monitoring: a reference laboratory experience.
@nl
type
label
Posaconazole therapeutic drug monitoring: a reference laboratory experience.
@en
Posaconazole therapeutic drug monitoring: a reference laboratory experience.
@nl
prefLabel
Posaconazole therapeutic drug monitoring: a reference laboratory experience.
@en
Posaconazole therapeutic drug monitoring: a reference laboratory experience.
@nl
P2093
P2860
P356
P1476
Posaconazole therapeutic drug monitoring: a reference laboratory experience.
@en
P2093
Gennethel Pennick
George R Thompson
James S Lewis
Michael G Rinaldi
Sheryl A Dorsey
Thomas F Patterson
P2860
P304
P356
10.1128/AAC.00240-09
P407
P577
2009-03-02T00:00:00Z